--- title: "28 stocks received buy ratings from brokerages, with Jiuzhou Pharma's target increase reaching 57.75%" type: "News" locale: "en" url: "https://longbridge.com/en/news/251925775.md" description: "On August 6th, a total of 28 stocks received buy ratings from brokerages, with Jiuzhou Pharma having the highest target increase of 57.75%. Tiantan Biological and CHINA PET FOODS had target increases of 55.87% and 20.65%, respectively. The ratings for 20 stocks remained unchanged, while 8 were rated for the first time. CHINA PET FOODS and Shanghai Pudong Development Bank received attention from 4 and 3 brokerages, respectively. The sectors with the most buy-rated stocks were food, beverages and tobacco, materials II, and banking" datetime: "2025-08-07T00:33:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/251925775.md) - [en](https://longbridge.com/en/news/251925775.md) - [zh-HK](https://longbridge.com/zh-HK/news/251925775.md) generator: "portal-rs" --- # 28 stocks received buy ratings from brokerages, with Jiuzhou Pharma's target increase reaching 57.75% On August 6th, a total of 28 stocks received buy ratings from brokerages, among which 7 stocks announced target prices. Based on the highest target price, Jiuzhou Pharma, Tiantan Biological, and CHINA PET FOODS ranked highest in target price increase, with increases of 57.75%, 55.87%, and 20.65%, respectively. In terms of rating adjustments, 20 stocks maintained their ratings, while 8 stocks received ratings for the first time. Additionally, 2 stocks attracted attention from multiple brokerages, with CHINA PET FOODS and Pudong Development Bank receiving the most ratings, with 4 and 3 brokerages providing ratings, respectively. From the perspective of the Wind industry to which the stocks with buy ratings belong, the sectors with the most buy-rated stocks are food, beverage and tobacco, materials II, and banking, with 4, 3, and 3 stocks, respectively ### Related Stocks - [002891.CN](https://longbridge.com/en/quote/002891.CN.md) - [603456.CN](https://longbridge.com/en/quote/603456.CN.md) ## Related News & Research - [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md) - [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md) - [HENGRUI PHARMA 1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md) - [REG - Windar Photonics PLC - Result of Placing & Direct Subscription](https://longbridge.com/en/news/296816414.md) - [08:36 ETUltimate Men's HQ Launches Private Product-Match Education Experience](https://longbridge.com/en/news/296789283.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**